Abstract: Objective To explore the clinical efficacy and adverse reactions associated with transcatheter arterial chemoembolization （TACE）combined with sorafenib in advanced hepatocellular carcinoma（HCC）. Methods A total of 70 patients with advanced and late HCC were divided into two treatment groups: one received TACE combined with sorafenib， while the other was treated by TACE alone.Tumor response was assessed every 4-8 weeks using Response Evaluation Criteria for Solid Tumors（RECIST）.Clinical efficacy and adverse effects associated with sorafenib were evaluated. Median overall survival（OS） and median time to progression （TTP） were compared between the two groups. Results Median OS was significantly shorter in the combination therapy group（8.2 months）than in the TACE-only group（14.8 months；P<0.05）.The combination therapy group also showed significantly shorter median TTP（10.3 months vs 5.8 months，P<0.05）.The rate of adverse reactions in the combination therapy group was 77.1%. Conclusions TACE combined with sorafenib is effective for treating patients with advanced and late HCC，and it is associated with tolerable side effects.

Key words:  Liver neoplasms, Hepatocellular carcinoma, TACE, Sorafenib